Equities

Nagaileben Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Nagaileben Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)1,786.00
  • Today's Change-11.00 / -0.61%
  • Shares traded78.40k
  • 1 Year change-3.41%
  • Beta0.3731
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nagaileben Co Ltd is a Japan-based company mainly engaged in the planning, manufacture, and sale of various medical wear, as well as shoes and other products. It sells medical wear used by medical professionals and caregivers, which are products that it plans and develops itself, supplied by its manufacturing subsidiary. For some medical wear, it purchases and sells products produced overseas and domestically from its manufacturing subsidiary and general business partners. It also purchases and sells shoes from general business partners.

  • Revenue in JPY (TTM)16.69bn
  • Net income in JPY2.48bn
  • Incorporated1950
  • Employees501.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kusurinomadoguchi Inc11.71bn2.59bn29.25bn484.0011.282.927.132.50228.38228.381,033.34882.360.6939--3.1924,186,230.0015.71--26.98--56.02--22.65------0.158--28.41--133.66------
Mizuho Medy Co Ltd11.26bn3.43bn34.18bn187.009.981.839.263.04179.80179.80591.12980.860.52251.552.09--15.9027.7417.9633.0669.4474.5130.4336.696.46-------1.4821.77-9.2262.0723.87--
Rion Co Ltd27.94bn2.98bn35.85bn1.01k12.011.088.231.28241.73241.732,267.252,682.200.71751.673.8927,692,170.007.656.578.727.6249.5350.1110.669.273.55--0.0028.398.365.377.829.9520.048.61
Nippon Care Supply Co., Ltd.34.10bn2.17bn39.31bn1.45k17.372.094.211.15139.36139.362,194.671,155.761.26101.8030.3523,453,350.008.007.3711.529.8036.4536.776.356.340.7615--0.091359.8011.9410.8813.573.7013.338.76
Cyberdyne Inc4.11bn-3.00m43.16bn211.00--1.6768.4010.51-0.0142-0.014219.46188.520.08331.607.7019,469,190.00-0.1034-1.36-0.1056-1.3861.0857.96-1.24-20.8013.94--0.0108--0.68919.5960.91---5.51--
Win-Partners Co Ltd87.25bn2.14bn43.38bn630.0018.751.7117.980.497275.8575.853,098.48830.261.8321.984.45138,488,200.004.494.298.527.9211.9812.402.452.591.62--0.0068.005.644.759.981.5233.839.52
France Bed Holdings Co Ltd61.19bn2.72bn46.42bn1.81k18.651.135.830.758771.6571.651,627.811,177.550.90172.946.0633,769,870.004.014.195.055.6555.0053.374.454.781.951,504.330.244146.932.382.93-6.0014.15-2.507.39
Japan Eyewear Holdings Co Ltd17.99bn4.22bn47.47bn580.0011.392.797.922.64172.64172.64736.69704.930.47411.8016.5631,022,410.0011.13--12.75--79.15--23.48--0.785318.060.4966--23.20--80.15------
Medikit Co Ltd23.68bn3.09bn47.53bn989.0014.120.95029.712.01211.98211.981,621.483,149.960.46433.144.1023,940,550.006.075.706.726.3038.5539.3713.0713.845.33--0.000241.813.222.54-1.820.854821.5712.47
Nagaileben Co Ltd16.69bn2.48bn55.23bn501.0022.291.4220.043.3180.6280.62544.001,263.590.38981.324.2033,321,640.005.786.906.137.4339.3743.3514.8418.6810.68--0.0067.123.48-0.097-8.81-5.8216.970.00
TAUNS Laboratories Inc14.92bn3.69bn55.44bn316.0015.343.1812.483.7133.9533.95139.96163.580.37210.91622.1347,226,430.009.20--13.12--64.90--24.72--0.948831.130.56--1.05--9.38------
Kitazato Corp10.98bn3.98bn62.08bn86.0015.583.2014.895.6599.6099.60274.45485.650.57231.838.92--20.77--21.73--66.93--36.29--14.33--0.00--2.20---4.63------
Shofu Inc38.97bn4.25bn64.60bn1.41k15.171.4111.921.66118.98118.981,092.321,279.850.75741.239.8127,577,490.008.287.279.278.2459.4558.4110.949.752.72--0.0032.9910.318.1918.1143.72-3.1930.39
Data as of Feb 17 2026. Currency figures normalised to Nagaileben Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

28.53%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 28 Nov 20252.86m9.30%
First Eagle Investment Management LLCas of 28 Nov 20252.10m6.82%
Burgundy Asset Management Ltd.as of 31 Jan 2026850.10k2.77%
The Vanguard Group, Inc.as of 04 Feb 2026762.72k2.48%
Nomura Asset Management Co., Ltd.as of 05 Feb 2026717.30k2.33%
Kamakura Investment Management Co., Ltd.as of 22 Jul 2025342.10k1.11%
Amova Asset Management Co., Ltd.as of 06 Feb 2026334.30k1.09%
FIAM LLCas of 30 Nov 2025329.89k1.07%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026320.40k1.04%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Feb 2026155.70k0.51%
More ▼
Data from 22 Jul 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.